We work Hard to get you posted with latest updates

http://We%20work%20Hard%20to%20get%20you%20posted%20with%20latest%20updates

Spend time learning about the different aspects of that topic from experts in the field.

AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy

Unwrap our new Directory

Hang Seng Index

Bio-Pharma

Innovent Biologics Joins Hang Seng Index, Marking Biopharma Breakthrough

SuZhou, China – Nov. 24, 2025 — Innovent Biologics (01801.HK), a leading Chinese biopharmaceutical company focused on oncology, cardiovascular/metabolic,...

By cGxPwire Editor
November 24, 2025

Recent Posts

01

.Clinical

Can-Fite Reports Positive Final Phase IIa Data for Namodenoson in Advanced Pancreatic Cancer
October 27, 2026
02

.Clinical

Longeveron Reports Significant Reduction in Major Adverse Cardiac Events in ELPIS II HLHS Trial
October 27, 2026
03

Bio-Pharma

Roche Reports Survival Gains With Divarasib in Lung Cancer
October 27, 2026
04

Bio-Pharma

Alebund and R1 Advance AP306 Phase 2b Kidney Trial
October 27, 2026
05

.Clinical

Serapha Bio Reports Positive Interim Safety and Efficacy Results for SERP-01 in Alpha-1 Antitrypsin Deficiency
October 27, 2026